Business Wire

RoboSense Releases the Latest Version of its Sensor Evaluation System for Autonomous Driving

9.2.2021 22:00:00 EET | Business Wire | Press release

Share

RoboSense LiDAR (https://robosense.ai/) today released the latest version of the ground truth data system and evaluation tool chain RS-Reference 2.1, used for LiDARs and multi-sensor fusion systems performance evaluation. The original RS-Reference version was launched in the market in 2016, when the automotive-grade MEMS solid-state LiDAR RS-LiDAR-M1 project was established. Used by global OEMs and Tier1s, the system has been continuously improved and upgraded with more efficient and useful evaluation function modules and software tool chains.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005689/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

While the evaluation function modules can be liked to an exam, the ground truth data is the "answer" for the evaluation of the perception system. Therefore, the accuracy of ground truth data must be significantly higher than the device under test (DuT) in all aspects including detection performance and geometric error.

The ground truth data, usually stored in the PB-Level, includes dynamic information such as obstacle types, speeds, and locations, and static information such as lane lines and road boundaries.

Data labeling quality and data generation efficiency are the key factors to ground truth data.

  • The RS-Reference system provides a set of ground truth data generation and evaluation solutions, and outputs detection performance and geometric error indicators with a labeling efficiency close to 1:1. This is significantly more accurate than real-time perception, manual labeling and traditional labeling tools.
  • High performance and mature sensor data collection system: the RS-Reference system contains the RoboSense 128-beam LiDAR RS-Ruby, Leopard camera, Continental 408 millimeter-wave radar, GI-6695 RTK, and two added RoboSense RS-Bpearl LiDAR for near-field blind spots in the 2.1 version.
  • Detached roof-mounted deployment without vehicle body modification: the RS-Reference system adapts to different vehicle sizes, does not occupy the sensor installation position of the DuTs, and directly evaluates the intelligent driving system that is consistent with the sensor sets of commercial vehicles.
  • Vastly improved/accumulated perception algorithm and offline processing mechanism: The algorithm is key to smart labeling instead of manual labeling, and is responsible for the extraction of ground truth data. The RS-Reference system uses a customized and dedicated offline perception algorithm, which is the product of RoboSense’s 13+ years’ of accumulated experience of LiDAR sensing algorithm technology. It performs a “full life process tracking and identification" for each obstacle data, and extracts all ground truth data from each frame. The RS-Reference system can pick up speed and acceleration labeling, and accurately delineate the size of the labeling frame through comprehensive shape and size information. The system is also capable of accurately dividing obstacles that are in close proximity to each other in complex scenes.
  • Full-stack evaluation tool chain: it includes data collection tools, sensor calibration tools, visualization tools, manual verification tools, evaluation tools, etc. The 2.1 version upgrades the data management platform and adds the scene semantic labeling function that serves every step of the evaluation process.
  • Individual sensor evaluation in the multi-sensor fusion system: not only can the RS-Reference system evaluate the result of intelligent driving's perception fusion, but it can also provide targeted solutions based on the features of different types of sensors such as LiDAR, millimeter wave radar, and camera. Dedicated or customized tool modules can be developed according to customer needs for further in-depth analysis of the performance of the sensing system.
  • Extended application value of the RS-Reference: includes planning and control algorithm development support, which is able to generate massive ground truth data to build simulation scenes, and can evaluate road-side perception systems.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cassie Gong
sqgong@robosense.ai
86-15507590175

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye